| __timestamp | Ionis Pharmaceuticals, Inc. | Verona Pharma plc |
|---|---|---|
| Wednesday, January 1, 2014 | 20140000 | 1802274 |
| Thursday, January 1, 2015 | 37173000 | 2512761 |
| Friday, January 1, 2016 | 48616000 | 2894488 |
| Sunday, January 1, 2017 | 108488000 | 8096274 |
| Monday, January 1, 2018 | 244622000 | 7985229 |
| Tuesday, January 1, 2019 | 287000000 | 8994597 |
| Wednesday, January 1, 2020 | 354000000 | 29772000 |
| Friday, January 1, 2021 | 186000000 | 33907000 |
| Saturday, January 1, 2022 | 151000000 | 26579000 |
| Sunday, January 1, 2023 | 232600000 | 49868547 |
Infusing magic into the data realm
In the ever-evolving landscape of biopharmaceuticals, understanding the financial dynamics of key players is crucial. Ionis Pharmaceuticals, Inc. and Verona Pharma plc, two prominent names in the industry, have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Ionis Pharmaceuticals experienced a staggering increase of over 1,000% in SG&A costs, peaking in 2020. This reflects their aggressive expansion and investment in research and development. In contrast, Verona Pharma's SG&A expenses, while also increasing, grew at a more modest pace, highlighting a more conservative approach. By 2023, Ionis's expenses were nearly five times higher than Verona's, underscoring their differing strategies. This financial narrative not only reveals the companies' operational priorities but also offers insights into their market positioning and future growth trajectories.
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited and Verona Pharma plc: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Verona Pharma plc
Comparing SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ionis Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Verona Pharma plc
Ionis Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
Breaking Down SG&A Expenses: Verona Pharma plc vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Verona Pharma plc and Protagonist Therapeutics, Inc.
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.